Clinical trial: Inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 10, 2010, Pages 1618-1625

  Kim, Hyung Keun ^a   Park, Soo Heon ^b   Cheung, Dae Young ^b   Cho, Young Seok ^a   Kim, Jin Il ^b   Kim, Sung Soo ^a   Chae, Hiun Suk ^a   Kim, Jae Kwang ^b   Chung, In Sik ^b  

^a Uijeongbu St Mary's Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

acid pump antagonist; proton pump inhibitor; revaprazan

Indexed keywords

GASTRIN; REVAPRAZAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG ELIMINATION; GASTRIN BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH PH; TREATMENT DURATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; GASTRIC PH MONITORING; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77957592824     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06408.x     Document Type: Article

References (27)

1. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990 99 : 345 351.
2. Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992 33 : 118 124.
3. Horn J. The proton-pump inhibitors: similarities and differences. Clin. Ther. 2000 22 : 266 279.
4. +-ATPase. J. Physiol. 2000 94 : 19 23.
5. Ene MD, Khan-Daneshmend T, Roberts CJ. A study of the inhibitory effects of SCH28080 on gastric secretion in man. Br. J. Pharmacol. 1982 76 : 389 391.
6. Beil W, Hackbarth I, Sewing KF. Mechanism of gastric antisecretory effect of SCH28080. Br. J. Pharmacol. 1986 88 : 19 23.
7. Keeling DJ, Malcolm RC, Laing SM, Ife RJ, Leach CA. SK&F 96067 is a reversible, lumenally acting inhibitor of the gastric (H+/K+)-ATPase. Biochem. Pharmacol. 1991 42 : 123 130.
8. +-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F97574. I. In vitro activity. Biochem. Pharmacol. 1995 50 : 1543 1549.
9. Han KS, Choi HC, Yoo JK, Lee JW, Lee MG. Determination of a new proton pump inhibitor, YH1885, in human plasma and urine by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1997 696 : 312 316.
10. Han KS, Kim YG, Yoo JK, Lee JW, Lee MG. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats. Biopharm. Drug. Dispos. 1998 19 : 493 500.
11. Han KS, Kim YG, Lee JW, Lee MG. Blood partition and protein binding of a new reversible proton pump inhibitor, YH1885. Biopharm. Drug. Dispos. 1998 19 : 413 415.
12. Park S, Lee SM, Song K, Lee B, Kang H, Kang J. The pharmacological properties of a novel acid pump antagonist, YH1885. Gut 2003 52 (Suppl. VI A62.
13. Fackler WK, Vaezi MF, Richter JE. Ambulatory gastric pH monitoring: proper probe placement and normal values. Aliment. Pharmacol. Ther. 2001 15 : 1155 1162.
14. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment. Pharmacol. Ther. 2003 17 : 1507 1514.
15. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24 h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol. Ther. 1998 12 : 1079 1089.
16. Cederberg C, Röhss K, Lundborg P, Olbe L. Effect of once daily intravenous and oral omeprazole on 24 hour intragastric acidity in healthy subjects. Scand. J. Gastroenterol. 1993 28 : 179 184.
17. Bell NJ, Hunt RH. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. Aliment. Pharmacol. Ther. 1996 10 : 897 904.
18. Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J. Clin. Gastroenterol. 1997 24 : 65 70.
19. van Herwaarden MA, Samsom M, Smout AJ. 24 h recording of intragastric pH: technical aspects and clinical relevance. Scand. J. Gastroenterol. 1999 230 (Suppl 9 16.
20. Teyssen S, Pfutzer R, Stephan F, Singer MV. Comparison of the effect of a 28-day long term therapy with the proton pump inhibitor pantoprazole with the H2-receptor antagonist ranitidine on intragastric pH in healthy human subjects. Gastroenterol 1995 108 (Suppl A240.
21. Hartmann M, Theiss U, Huber R et al. Twenty-four hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment. Pharmacol. Ther. 1996 10 : 359 366.
22. Armstrong D, Bair D, James C, Tanser L, Escobedo S, Nevin K. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment. Pharmacol. Ther. 2003 18 : 705 711.
23. Yu KS, Bae KS, Shon JH et al. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J. Clin. Pharmacol. 2004 44 : 73 82.
24. Chung IS, Choi MG, Park SH et al. Revaprazan (Revanex®), a novel acid pump antagonist, for duodenal ulcer: results of a double-blind, randomized, parallel, multi-center phase III clinical trial. Korean J. Gastrointest. Endosc. 2005 31 : 17 24.
25. Choi MG, Park SH, Kim SK et al. Phase III clinical trial of revaprazan (Revanex®) for gastritis. Korean J. Gastrointest. Endosc. 2006 33 : 212 219.
26. Chang R, Chung IS, Park SH et al. Phase III clinical trial of revaprazan (Revanex®) for gastric ulcer. Korean J. Gastrointest. Endosc. 2007 34 : 312 319.
27. Wurst W, Hartmann M. Current status of acid pump antagonists (reversible PPIs). Yale J. Biol. Med. 1996 69 : 233 243.